Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
50.74 USD | -1.93% | -2.57% | -18.04% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.04% | 11.62B | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-20.96% | 29.36B | |
+57.67% | 24.49B | |
-13.66% | 17.31B | |
-13.96% | 11.31B | |
-44.23% | 11.26B | |
+6.07% | 8.31B | |
-9.82% | 7.9B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation(NasdaqGS: INCY) added to Russell 1000 Growth-Defensive Index